LYP-IN-3

LYP-IN-3

• UNSPSC Description: LYP-IN-3 (compound D34) is a selective inhibitor of Lymphoid-tyrosine phosphatase (LYP) (Ki=0.93 μM), and regulates T-cell receptor (TCR) signaling pathway in tumor progress. LYP-IN-3 activates T-cell and inhibits M2 macrophage polarization, but upregulates PD-1/PD-L1 expression. LYP-IN-3 can be leveraged with PD-1/PD-L1 inhibitor, for futher cancer immunotherapy[1].
• Target Antigen: Phosphatase
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/lyp-in-3.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(C1=CC2=CC(N(CC3=CC=C(OCC4=CC=CC=C4)C=C3)S(=O)(C5=CC=C(C6=CC=CC=C6)C=C5)=O)=CC=C2O1)O
• Molecular Weight: 589.66
• References & Citations: [1]Liang X, et al. Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy. Eur J Med Chem. 2023 Oct 5;258:115599.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported